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(and / or its cellular source) will likely be 
required in order (1) to prevent 
 recurrence of complement-mediated 
injury and (2) to prevent graft  pathology 
induced by complement-independent 
mechanisms initiated by the alloanti-
body. Newer agents targeting B cells and 
plasma cells, including proteosome 
inhibitors that are currently being tested 
in transplantation, 4 may prove to be 
more effi  cacious than currently available 
reagents for this purpose. 
 Th e report by Tillou  et al. 6 represents a 
small but important step toward develop-
ing an eff ective therapeutic strategy for 
antibody-mediated transplant rejection. 
Th e fi ndings support further development 
and testing of the safety and effi  cacy of 
complement inhibition as part of a 
comprehensive strategy to treat this 
disease in humans. 
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 Regulation of salt reabsorption in the 
distal nephron, that is, the tubular seg-
ments located beyond the macula densa, 
plays a key role in defi ning the fi nal con-
centration of salt in urine and thus, on a 
long-term basis, helps defi ne blood pres-
sure levels. To date, all monogenic dis-
eases featuring arterial hypertension or 
hypotension in which the diseased gene 
has been discovered are due to muta-
tions in genes that encode proteins 
known to be directly involved in salt rea-
bsorption in the distal nephron. One of 
these genes is  SLC12A3 , encoding the 
thiazide-sensitive Na   +   – Cl   −   cotrans-
porter (NCC), which is heavily expressed 
in the apical membrane of the distal 
 convoluted tubule (DCT). Th e activity of 
NCC is important for salt reabsorption 
and also for potassium secretion, because 
the salt reabsorption rate in the DCT 
defi nes sodium delivery to the collecting 
duct, which is necessary for the sodium /
 potassium exchange between the epithe-
lial sodium channel, ENaC, and the 
apical potassium channels ROMK and 
BK in order to promote potassium secre-
tion. Th e importance of NCC in blood 
pressure regulation has been clearly dem-
onstrated over the years, as inhibition of 
NCC with thiazides reduces blood pres-
sure in many hypertensive patients. 
Additionally, inactivating mutations 
of the  SLC12A3 gene are the cause of 
Gitelman ’ s disease, an inherited syndrome 
featuring arterial hypotension and 
hypokalemia. On the other hand, loss of 
proper regulation of NCC by the mutant 
with-no-lysine serine / threonine kinases 
(WNKs) WNK1 and WNK4 seems to be 
an important mechanism for the devel-
opment of the arterial hypertension and 
hyperkalemia seen in pseudohypoaldos-
teronism type II. 1 Th us, modulation of 
NCC activity is a growing fi eld of study, 
since as we learn about how this cotrans-
porter is regulated, we increase the pos-
sibilities for understanding complex 
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 Vasopressin is a modulator of salt and water reabsorption, with known 
effects in the thick ascending limb and the collecting duct. Pedersen 
 et al. present evidence that vasopressin administration increases the 
phosphorylation of the apical thiazide-sensitive Na   +   – Cl   −   
cotransporter in the distal convoluted tubule. These effects appear to 
be independent of the renin – angiotensin system and to be mediated 
by the intracellular kinase SPAK. These observations expand the 
vasopressin-sensitive region of the nephron. 
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diseases such as essential hypertension and 
developing newer antihypertensive drugs 
and strategies. 
 Major advances have been produced 
in the past decade regarding modulation 
of NCC. The activity of this cotrans-
porter, as well as the closely related 
members of its family, the Na   +   – K   +   –
 2Cl   −   cotransporters NKCC1 and 
NKCC2, is associated with phosphoryla-
tion of certain conserved threonine 
residues  in the amino-terminal 
domain. 2 – 4 Th us, antibodies recognizing 
these threonines when phosphorylated 
(phosphoantibodies) can now be used as 
a tool to indirectly assess activity of these 
cotransporters in several  in vitro and 
 in vivo models. In rat NCC, threonine-
53 (T53), T58, and serine-71 (S71) have 
been recognized as the most important 
ones, corresponding to T55, T60, and 
S73 in humans. 2,5 So far, the kinases 
that seem to be responsible for the 
phosphoryla tion of these sites are the 
STE20-related kinases known as STE20 /
 SPS1-related proline-alanine-rich kinase 
(SPAK) and oxidative stress-responsive 
kinase-1 (OSR1). Consistent with this, a 
recent report shows that elimination of 
SPAK ’ s activity in mice produces a 
 Gitelman-like syndrome, with arterial 
hypotension and hypokalemia, 6 due to a 
decreased expression and phosphoryla-
tion of NCC. SPAK and OSR1 lie down-
stream of the WNKs, 4,7 kinases that 
cause pseudohypoaldosteronism type II, 
which presents with arterial hyperten-
sion. Th us, the current paradigm is that 
WNKs (WNK3, WNK4) interact with 
and phosphorylate SPAK, which in turn 
phosphorylates NCC, increasing its 
activity. It has not been clearly estab-
lished whether NCC (or NKCC1 / 2) 
phosphorylation at amino-terminal 
threonine residues increases the traffi  ck-
ing of the cotransporter to the plasma 
membrane or the activity of the trans-
porters already in the membrane. 
 Most of the hormones that modulate 
blood pressure levels do so by aff ecting 
vascular smooth muscle contraction 
and / or urinary salt and water meta-
bolism. Examples are the renin –
 angiotensin – aldosterone system, the 
sympathetic nervous system, and atrial 
natriuretic peptide. Vasopressin is 
another hormone that has clear eff ects 
on both blood vessels and renal tubules. 
While this peptide produces vasocon-
striction by activating G  q-coupled V 1 
membrane receptors in blood vessels, it 
also increases salt reabsorption in the 
thick ascending limb and water in the 
collecting duct, through activation of its 
G  s-coupled V 2 membrane receptors 
( Figure 1 ). The main consequence of 
these renal actions, however, is the urine 
concentration ability, rather than modu-
lation of arterial blood pressure. Th us, 
an eff ect of vasopressin on the DCT to 
increase salt reabsorption has been sug-
gested for years and is supported by 
some physiological studies, but elucida-
tion of such effects has been limited 
because of the absence of reliable culture 
cells from the DCT. 
 Pedersen  et al. 8 (this issue) now 
present compelling evidence that vaso-
pressin positively modulates NCC 
activity. The authors took advantage of 
the fact that NCC phosphorylation at 
the amino-terminal domain threonines 
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 Figure 1  |  Known vasopressin actions in the nephron. Vasopressin is well known for its 
activation properties in renal tubules via its interaction with the V 2 -type receptor, particularly 
in the thick ascending limb of Henle (TAL) and collecting duct (CD). Pedersen  et al. 8 show that 
vasopressin is also an activator of the Na   +   – Cl   −   cotransporter (NCC) in the distal convoluted 
tubule (DCT). ( a ) The DCT in the absence of vasopressin. ( b ) The DCT in the presence of 
vasopressin. 
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has become a useful molecular tool to 
indirectly assess NCC activity. In this 
study, phosphoantibodies directed 
against phosphorylated NCC at T53 
and T58 were raised and characterized. 
Using this tool, the authors made a 
series of interesting observations. First, 
acute or chronic treatment of arginine 
vasopressin (AVP)-deficient Brattle-
boro rats with the V 2 receptor-selective 
analog 1-desamino-8-D-arginine-AVP 
(dDAVP) significantly increased phos-
phorylation of NCC at T53 and T58. 
This observation strongly suggests that 
vasopressin modulates NCC activity. 
Second, by means of immunohisto-
chemistry and immunogold electron 
microscopy of Brattleboro kidney sec-
tions, the authors observed that dDAVP 
induces phosphorylation of NCC par-
ticles that are already in the membrane, 
but not of those in the submembranal 
space. In other words, they propose 
that dDAVP does not alter the subcel-
lular distribution of NCC, implying 
that phosphorylation of NCC is asso-
ciated with increased activity of trans-
porters that are already in the apical 
membrane, rather than stimulating 
trafficking of NCC vesicles. Third, the 
authors show that an effect of dDAVP 
is present even in rats in which angio-
tensin II actions have been maximally 
reduced by a high-salt diet and treat-
ment with the angiotensin type 1 recep-
tor blocker candesartan, reducing the 
possibility that vasopressin effects are 
due to act ivat ion of  the renin –
 angiotensin system. They also show a 
transient increase of intracellular cal-
cium induced by dDAVP on isolated 
distal tubules, suggesting a direct effect 
of vasopressin in the DCT that requires 
no intermediaries. The effect was much 
more intense in the late DCT than in 
the early DCT. Finally, by using specific 
antibodies to recognize the total and 
phosphorylated SPAK and OSR1 kinase 
on residues T240 / T185 and S380 / S325, 
the authors observed that dDAVP 
administration was associated with a 
slight but significant increase in SPAK 
and OSR1 phosphorylation, suggesting 
that SPAK and OSR1 are involved in 
the vasopressin-induced phosphoryla-
tion of NCC. 
 The results presented by Pedersen 
 et al. 8 represent an advance in our 
knowledge of NCC modulation by a 
hormone produced outside the kidney, 
and also in our understanding of the 
diverse eff ects vasopressin has in diff er-
ent regions of the nephron. With this 
information we can now consider vaso-
pressin as a hormone that has a positive 
eff ect on salt and water reabsorption all 
the way from the thick ascending limb 
of Henle to the collecting duct ( Figure 1 ). 
Interestingly, a recent publication by 
another group 9 using a similar model of 
Brattleboro rats treated with dDAVP 
presented evidence that vasopressin 
induces activation of NCC by increasing 
phosphorylation of T53 and S71. S71 is 
another phosphoacceptor site that has 
been shown to be associated with 
increased activity of NCC when phos-
phorylated. 2 Although both reports 
agree on the major message that vaso-
pressin activates NCC, intriguingly, 
there are some observations that are 
completely opposite from one study to 
the other. Pedersen  et al. 8 suggest that 
vasopressin induces phosphorylation of 
NCC that is already located in the apical 
plasma. Th is observation is supported 
by a study using  Xenopus laevis oocytes 2 
in which induction or prevention of 
NCC phosphorylation at T53, T58, or 
S71 was associated with increased or 
decreased activity of NCC, respectively, 
without affecting its amount in the 
plasma membrane. In contrast, Mutig 
 et al. 9 suggest that vasopressin modu-
lates the traffi  cking of NCC particles to 
the apical membrane. Th is is supported 
by the previous observation that vaso-
pressin increases traffi  cking of NKCC2 
to the plasma membrane by inducing 
phosphorylation of the same residues. 10 
Th ere is a slight diff erence in the route 
and dose of dDAVP administration 
between the two studies, but it is 
unlikely that this could be the explana-
tion for the opposite results. Another 
interesting diff erence is the location of 
the vasopressin effect on the DCT. 
According to Pedersen  et al. , 8 the eff ect 
of vasopressin was observed in both 
DCT1 and DCT2 and was more inten-
sive in DCT2, whereas Mutig  et al. 9 
present evidence that the vasopressin 
effect occurs only in DCT1. More 
detailed analysis of this issue is required, 
but, as was mentioned earlier, both 
studies agree on the major message that 
vasopressin modulates NCC activity. 
 Finally, it is interesting that the 
observations of Pedersen  et al. 8 suggest 
that vasopressin activates NCC by 
phosphorylating the cotransporter 
through the SPAK / OSR1 kinases. Since 
it is known that SPAK and OSR1 lie 
downstream of the WNK kinases, 4,5,7 
it is possible that vasopressin ’ s activa-
tion of its G  s-coupled receptor modu-
lates the activity and phosphorylation 
of the WNKs. 
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